Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

The department is conducting trials that explore novel interventions for endocrine‑related conditions such as Graves’ disease and advanced prostate malignancies, aiming to improve disease control and patient quality of life.

• Graves’ Disease
• High‑risk prostate cancer with BRCA mutation
• Prostate cancer undergoing androgen deprivation therapy

Research at Narodowy Instytut Onkologii Im. Marii Sklodowskiej‑Curie focuses on evaluating new hormonal agents and combination strategies to enhance therapeutic outcomes.

Studies in this area target autoimmune and hematologic disorders, including the use of innovative biologics and cell‑based therapies to modulate immune activity.

• Systemic lupus erythematosus
• Lupus nephritis
• Severe refractory idiopathic inflammatory myopathies
• Non‑Hodgkin lymphoma

The trials aim to assess safety and efficacy of agents such as efgartigimod PH20 and CAR‑T cell therapies, providing new options for patients with immune‑mediated diseases.

Clinical research is centered on improving outcomes for cancers of the male reproductive system, particularly through targeted and immunotherapeutic approaches.

• Prostate cancer

Investigators evaluate combinations like sarupirb (AZD5305) with standard radiation and androgen deprivation, seeking to reduce metastasis risk in high‑risk patients.

A broad portfolio of oncology trials investigates cutting‑edge treatments for solid tumors, ranging from melanoma to gastrointestinal cancers, with a focus on enhancing survival and response rates.

• Advanced melanoma
• Head and neck squamous cell carcinoma
• Ovarian, fallopian tube, or primary peritoneal carcinoma
• Cervical cancer
• Metastatic colorectal cancer
• Adenoid cystic carcinoma of the salivary glands

The site evaluates agents such as pembrolizumab, paclitaxel, and novel kinase inhibitors, striving to establish more effective first‑line and maintenance regimens.

Research in this field concentrates on head and neck malignancies, employing immunotherapy and targeted drugs to improve local control and overall survival.

• Recurrent or metastatic PD‑L1 positive head and neck squamous cell carcinoma
• Incurable metastatic/recurrent head and neck cancer after prior PD‑1 therapy
• Adenoid cystic carcinoma of the salivary glands

Trials compare strategies like petosemtamab plus pembrolizumab versus standard care, aiming to set new standards for patients with difficult‑to‑treat otorhinolaryngologic tumors.